Rank,Term name,P-value,Z-score,Combined score,Overlapping genes,Adjusted p-value,Old p-value,Old adjusted p-value,gene count
1,Macrophage markers WP4146,0.0007037268045589916,24.62578125,178.76150953139532,"['CD163', 'CD14', 'CD68']",0.1033600704000994,0,0,3
2,Microglia Pathogen Phagocytosis Pathway WP3937,0.000915146163638309,7.6443569553805775,53.48318359439692,"['NCF2', 'ARPC1B', 'NCF4', 'ITGB2', 'CYBA']",0.1033600704000994,0,0,5
3,Hematopoietic Stem Cell Differentiation WP2849,0.0012160008282364634,7.115802335052946,47.76260172247269,"['RHOH', 'FOSB', 'ACVR1B', 'GATA1', 'RUNX1']",0.1033600704000994,0,0,5
4,Pathogenesis of SARS-CoV-2 Mediated by nsp9-nsp10 Complex WP4884,0.001965283130073869,15.38671875,95.89186161542331,"['ZAP70', 'CD4', 'HLA-DRB1']",0.12528679954220917,0,0,3
5,Cancer immunotherapy by PD-1 blockade WP4585,0.004110076396386112,11.187144886363637,61.465682995956364,"['ZAP70', 'HLA-DRB1', 'BATF']",0.1789099031362835,0,0,3
6,Vitamin D Receptor Pathway WP2877,0.004209644779677259,3.3524085476276713,18.33893864781153,"['LRRC25', 'COLEC11', 'CRACR2A', 'ALOX5', 'TNFAIP3', 'TNFRSF11B', 'CD14', 'HLA-DRB1']",0.1789099031362835,0,0,8
7,Cytosine methylation WP3585,0.008105051097832425,20.443579766536963,98.44131176174515,"['TDG', 'IDH2']",0.25834850374340856,0,0,2
8,Purine metabolism WP4792,0.008105051097832425,20.443579766536963,98.44131176174515,"['PNP', 'ITPA']",0.25834850374340856,0,0,2
9,TYROBP causal network in microglia WP3945,0.010109055123289882,4.118897637795276,18.92354907610831,"['CD4', 'NCF2', 'ITGB2', 'IL18', 'SLC1A5']",0.28642322849321333,0,0,5
10,Cytokines and Inflammatory Response WP530,0.022820347737013944,10.217898832684824,38.62470692905383,"['CD4', 'HLA-DRB1']",0.5290171520853233,0,0,2
11,LTF danger signal response pathway WP4478,0.022820347737013944,10.217898832684824,38.62470692905383,"['MAPK1', 'CD14']",0.5290171520853233,0,0,2
12,Purine metabolism and related disorders WP4224,0.0274548177256515,9.081712062256809,32.65069487458085,"['PNP', 'ITPA']",0.5755066786213194,0,0,2
13,Ebola Virus Pathway on Host WP4217,0.02933955616500844,3.068809495827947,10.829272132098065,"['HLA-B', 'MAPK1', 'HLA-DOA', 'IKBKE', 'HLA-DRB1']",0.5755066786213194,0,0,5
14,T-cell receptor (TCR) signaling pathway WP69,0.035933674468453025,3.4196078431372547,11.373890676310541,"['ZAP70', 'CD4', 'MAPK1', 'CRKL']",0.6414072616269878,0,0,4
15,Kallmann's Syndrome WP5074,0.03772983891923458,7.429076759816059,24.347343087614725,"['MAPK1', 'GNRH1']",0.6414072616269878,0,0,2
16,Cytosolic DNA-sensing pathway WP4655,0.04413009420676039,4.09453125,12.777448761785639,"['RNF125', 'IL18', 'IKBKE']",0.6560830278316088,0,0,3
17,Modulators of TCR signaling and T cell activation WP5072,0.054828879568833276,3.7212357954545454,10.804750374153715,"['ZAP70', 'TNFAIP3', 'RHOH']",0.6560830278316088,0,0,3
18,Eicosanoid Synthesis WP167,0.05538340026993437,5.835464146748193,16.884771747550158,"['ALOX5', 'ALOX5AP']",0.6560830278316088,0,0,2
19,FBXL10 enhancement of MAP/ERK signaling in diffuse large B-cell lymphoma WP4553,0.05538340026993437,5.835464146748193,16.884771747550158,"['MAPK1', 'HIST1H3E']",0.6560830278316088,0,0,2
20,Kit receptor signaling pathway WP304,0.06258441275576558,3.5079241071428573,9.721296197862328,"['DOK1', 'MAPK1', 'CRKL']",0.6560830278316088,0,0,3
21,B Cell Receptor Signaling Pathway WP23,0.06772797341319901,2.732549019607843,7.356721459876614,"['MAPK1', 'E2F3', 'PIK3AP1', 'CRKL']",0.6560830278316088,0,0,4
22,mir-124 predicted interactions with cell cycle and differentiation  WP3595,0.07042352658532744,20.368217054263567,54.041521500805814,['CTDSP1'],0.6560830278316088,0,0,1
23,Association Between Physico-Chemical Features and Toxicity Associated Pathways WP3680,0.07081845760847824,3.317673141891892,8.783989558036438,"['FZD9', 'MAPK1', 'NEFH']",0.6560830278316088,0,0,3
24,Complement system WP2806,0.07408694232579711,2.6438962681846934,6.88078228512325,"['FCGR3A', 'ITGB2', 'F11', 'VSIG4']",0.6560830278316088,0,0,4
25,Glucocorticoid Receptor Pathway WP2880,0.07951207781220312,3.1469350961538463,7.967556126482695,"['GPR153', 'ALOX5AP', 'TNFAIP3']",0.6560830278316088,0,0,3
26,Allograft Rejection WP2328,0.08864499006646731,2.992854420731707,7.252032719323101,"['HLA-B', 'HLA-DOA', 'HLA-DRB1']",0.6560830278316088,0,0,3
27,Metabolism of alpha-linolenic acid WP4586,0.09278235579734741,13.577519379844961,32.28053587996539,['ALOX5'],0.6560830278316088,0,0,1
28,BDNF-TrkB Signaling WP3676,0.0971435336027785,4.082490272373541,9.518594152206767,"['DLG4', 'MAPK1']",0.6560830278316088,0,0,2
29,Common Pathways Underlying Drug Addiction WP2636,0.0971435336027785,4.082490272373541,9.518594152206767,"['MAPK1', 'DRD1']",0.6560830278316088,0,0,2
30,Prion disease pathway WP3995,0.0971435336027785,4.082490272373541,9.518594152206767,"['MAPK1', 'BATF']",0.6560830278316088,0,0,2
31,Signaling of Hepatocyte Growth Factor Receptor WP313,0.10477084893627563,3.887715397443024,8.770607034645009,"['MAPK1', 'CRKL']",0.6560830278316088,0,0,2
32,Amyotrophic lateral sclerosis (ALS) WP2447,0.11255419109928591,3.710647329324372,8.10524293567417,"['SLC1A2', 'NEFH']",0.6560830278316088,0,0,2
33,TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer WP2868,0.11460542540197254,10.182170542635658,22.057230121509917,['MAPK1'],0.6560830278316088,0,0,1
34,"Cerebral organic acidurias, including diseases WP4519",0.11460542540197254,10.182170542635658,22.057230121509917,['IDH2'],0.6560830278316088,0,0,1
35,Metastatic brain tumor WP2249,0.11460542540197254,10.182170542635658,22.057230121509917,['E2F3'],0.6560830278316088,0,0,1
36,Acute viral myocarditis WP4298,0.1184618340794286,2.6092918882978724,5.566048684214051,"['CD4', 'ITGB2', 'MAPK1']",0.6560830278316088,0,0,3
37,Regulatory circuits of the STAT3 signaling pathway WP4538,0.1184618340794286,2.6092918882978724,5.566048684214051,"['CSF3R', 'MAPK1', 'F2RL2']",0.6560830278316088,0,0,3
38,Sleep regulation WP3591,0.1204817193812252,3.5489764845203857,7.510547193938549,"['IL18', 'DRD1']",0.6560830278316088,0,0,2
39,Toll-like Receptor Signaling related to MyD88 WP3858,0.128542068394661,3.4007782101167314,6.9766932595646916,"['MAPK1', 'IKBKE']",0.6560830278316088,0,0,2
40,Fibrin Complement Receptor 3 Signaling Pathway WP4136,0.128542068394661,3.4007782101167314,6.9766932595646916,"['ITGB2', 'CD14']",0.6560830278316088,0,0,2
41,IL-2 signaling pathway WP49,0.128542068394661,3.4007782101167314,6.9766932595646916,"['MAPK1', 'CRKL']",0.6560830278316088,0,0,2
42,Corticotropin-releasing hormone signaling pathway WP2355,0.1291308940248617,2.502311862244898,5.12205398394346,"['IL18', 'MAPK1', 'FOSB']",0.6560830278316088,0,0,3
43,Regulation of toll-like receptor signaling pathway WP1449,0.13485508951114633,2.098340874811463,4.204140277272188,"['TNFAIP3', 'MAPK1', 'CD14', 'IKBKE']",0.6560830278316088,0,0,4
44,Bile acids synthesis and enterohepatic circulation  WP4389,0.1359055228314314,8.144961240310078,16.255675522667392,['MAPK1'],0.6560830278316088,0,0,1
45,Dual hijack model of Vif in HIV infection WP3300,0.1359055228314314,8.144961240310078,16.255675522667392,['RUNX1'],0.6560830278316088,0,0,1
46,Synaptic signaling pathways associated with autism spectrum disorder WP4539,0.14501804846764177,3.1385812630948817,6.060277371511026,"['DLG4', 'MAPK1']",0.6560830278316088,0,0,2
47,NO/cGMP/PKG mediated Neuroprotection WP4008,0.14501804846764177,3.1385812630948817,6.060277371511026,"['DLG4', 'CNGA3']",0.6560830278316088,0,0,2
48,Iron metabolism in placenta WP2007,0.15669513226697168,6.786821705426356,12.579056367910868,['HEPHL1'],0.6560830278316088,0,0,1
49,MFAP5-mediated ovarian cancer cell motility and invasiveness WP3301,0.15669513226697168,6.786821705426356,12.579056367910868,['MAPK1'],0.6560830278316088,0,0,1
50,Osteoclast Signaling WP12,0.15669513226697168,6.786821705426356,12.579056367910868,['TNFRSF11B'],0.6560830278316088,0,0,1
51,Metabolic reprogramming in colon cancer WP4290,0.16190012252391733,2.913841022790439,5.305450815809745,"['IDH2', 'SLC1A5']",0.6560830278316088,0,0,2
52,Proteasome Degradation WP183,0.16190012252391733,2.913841022790439,5.305450815809745,"['HLA-B', 'PSMB8']",0.6560830278316088,0,0,2
53,Toll-like Receptor Signaling Pathway WP75,0.1630000095869847,2.2280539772727272,4.0417010981766675,"['MAPK1', 'CD14', 'IKBKE']",0.6560830278316088,0,0,3
54,ErbB signaling pathway WP673,0.1630000095869847,2.2280539772727272,4.0417010981766675,"['SHC3', 'MAPK1', 'CRKL']",0.6560830278316088,0,0,3
55,IL-18 signaling pathway WP4754,0.16670726512139267,1.6607200085460956,2.9752063143150953,"['NCF2', 'IL18', 'TNFAIP3', 'MAPK1', 'TNFRSF11B', 'GATA1']",0.6560830278316088,0,0,6
56,TNF-alpha signaling pathway WP231,0.1688854196565046,2.1880580357142856,3.8915373263586392,"['TNFAIP3', 'MAPK1', 'CYBA']",0.6560830278316088,0,0,3
57,Novel intracellular components of RIG-I-like receptor (RLR) pathway WP3865,0.17046964439747644,2.8130953978263786,4.97692285526068,"['RNF125', 'IKBKE']",0.6560830278316088,0,0,2
58,Pre-implantation embryo WP3527,0.17046964439747644,2.8130953978263786,4.97692285526068,"['CELF3', 'FOSB']",0.6560830278316088,0,0,2
59,22q11.2 copy number variation syndrome WP4657,0.1748317482895096,2.149465460526316,3.7485198925786176,"['P2RX6', 'LRRC74B', 'CRKL']",0.6560830278316088,0,0,3
60,Cancer immunotherapy by CTLA4 blockade WP4582,0.17698644139895495,5.81672203765227,10.072713733468532,['HLA-DRB1'],0.6560830278316088,0,0,1
61,Classical pathway of steroidogenesis with glucocorticoid and mineralocorticoid metabolism WP4523,0.17698644139895495,5.81672203765227,10.072713733468532,['HSD11B2'],0.6560830278316088,0,0,1
62,IL-9 signaling pathway WP22,0.17698644139895495,5.81672203765227,10.072713733468532,['MAPK1'],0.6560830278316088,0,0,1
63,Osteoblast Signaling WP322,0.17698644139895495,5.81672203765227,10.072713733468532,['TNFRSF11B'],0.6560830278316088,0,0,1
64,T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection WP3863,0.1878214921599674,2.631103301117108,4.399897428476783,"['ZAP70', 'CD4']",0.6560830278316088,0,0,2
65,p53 transcriptional gene network WP4963,0.1878214921599674,2.631103301117108,4.399897428476783,"['NCF2', 'TNFRSF10D']",0.6560830278316088,0,0,2
66,Epithelial to mesenchymal transition in colorectal cancer WP4239,0.19012798944367057,1.816470588235294,3.015446177474274,"['CTDSP1', 'FZD9', 'MAPK1', 'WNT9A']",0.6560830278316088,0,0,4
67,Interferon type I signaling pathways WP585,0.19658726600041784,2.5486381322957197,4.14573927288002,"['ZAP70', 'CRKL']",0.6560830278316088,0,0,2
68,TCA Cycle (aka Krebs or citric acid cycle) WP78,0.19679134825528533,5.089147286821706,8.272975120267287,['IDH2'],0.6560830278316088,0,0,1
69,MAP3K1 role in promoting and blocking gonadal determination WP4872,0.19679134825528533,5.089147286821706,8.272975120267287,['MAPK1'],0.6560830278316088,0,0,1
70,MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement WP4560,0.19679134825528533,5.089147286821706,8.272975120267287,['MAPK1'],0.6560830278316088,0,0,1
71,Osteopontin Signaling WP1434,0.19679134825528533,5.089147286821706,8.272975120267287,['MAPK1'],0.6560830278316088,0,0,1
72,Breast cancer pathway WP4262,0.20494608682945895,1.7573687539531941,2.785444106003004,"['SHC3', 'FZD9', 'MAPK1', 'E2F3']",0.6560830278316088,0,0,4
73,Integrin-mediated Cell Adhesion WP185,0.20537666602834945,1.9751764112903225,3.126525684418714,"['SHC3', 'ITGB2', 'MAPK1']",0.6560830278316088,0,0,3
74,IL-3 signaling pathway WP286,0.20540249461985194,2.4711708524938096,3.911329282265569,"['MAPK1', 'CRKL']",0.6560830278316088,0,0,2
75,"GPCRs, Class A Rhodopsin-like WP455",0.21204849960182512,1.6096782193564387,2.4965147540613395,"['GPR65', 'OR7A5', 'GPR37L1', 'DRD1', 'F2RL2']",0.6560830278316088,0,0,5
76,Cardiac Hypertrophic Response WP2795,0.21425976815455777,2.3982604715037765,3.694678853852695,"['MAPK1', 'IKBKE']",0.6560830278316088,0,0,2
77,Pathogenic Escherichia coli infection WP2272,0.21425976815455777,2.3982604715037765,3.694678853852695,"['ARPC1B', 'CD14']",0.6560830278316088,0,0,2
78,RANKL/RANK signaling pathway WP2018,0.21425976815455777,2.3982604715037765,3.694678853852695,"['MAPK1', 'TNFRSF11B']",0.6560830278316088,0,0,2
79,"4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression WP3879",0.21612146799158877,4.523255813953488,6.9292419716887625,['MAPK1'],0.6560830278316088,0,0,1
80,"GPCRs, Class B Secretin-like WP334",0.21612146799158877,4.523255813953488,6.9292419716887625,['ADGRE1'],0.6560830278316088,0,0,1
81,Immune response to tuberculosis WP4197,0.21612146799158877,4.523255813953488,6.9292419716887625,['PSMB8'],0.6560830278316088,0,0,1
82,Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells WP4301,0.21612146799158877,4.523255813953488,6.9292419716887625,['MAPK1'],0.6560830278316088,0,0,1
83,MAPK and NFkB signaling pathways inhibited by Yersinia YopJ WP3849,0.21612146799158877,4.523255813953488,6.9292419716887625,['MAPK1'],0.6560830278316088,0,0,1
84,Omega-9 FA synthesis WP4724,0.21612146799158877,4.523255813953488,6.9292419716887625,['ELOVL3'],0.6560830278316088,0,0,1
85,3q29 copy number variation syndrome WP4906,0.22315200186729317,2.3295163979988884,3.494046576940065,"['PIGM', 'DYNLRB2']",0.6584832480926629,0,0,2
86,MET in type 1 papillary renal cell carcinoma WP4205,0.22315200186729317,2.3295163979988884,3.494046576940065,"['MAPK1', 'CRKL']",0.6584832480926629,0,0,2
87,PPAR signaling pathway WP3942,0.23207242496952832,2.264591439688716,3.3079018040236723,"['DBI', 'CPT1B']",0.6584832480926629,0,0,2
88,Effect of progerin on genes involved in Hutchinson-Gilford progeria syndrome WP4320,0.23498813951542089,4.0705426356589145,5.895042217515406,['HIST1H3E'],0.6584832480926629,0,0,1
89,ERK Pathway in Huntington's Disease WP3853,0.23498813951542089,4.0705426356589145,5.895042217515406,['MAPK1'],0.6584832480926629,0,0,1
90,Fatty acid transporters WP5061,0.23498813951542089,4.0705426356589145,5.895042217515406,['DBI'],0.6584832480926629,0,0,1
91,SARS coronavirus and innate immunity WP4912,0.23498813951542089,4.0705426356589145,5.895042217515406,['IKBKE'],0.6584832480926629,0,0,1
92,Selective expression of chemokine receptors during T-cell polarization WP4494,0.2534024320832485,3.700140944326991,5.079466214399331,['CD4'],0.6590539392586497,0,0,1
93,Serotonin Receptor 4/6/7 and NR3C Signaling WP734,0.2534024320832485,3.700140944326991,5.079466214399331,['MAPK1'],0.6590539392586497,0,0,1
94,Cells and molecules involved in local acute inflammatory response  WP4493,0.2534024320832485,3.700140944326991,5.079466214399331,['ITGB2'],0.6590539392586497,0,0,1
95,Hypertrophy Model WP516,0.2534024320832485,3.700140944326991,5.079466214399331,['IL18'],0.6590539392586497,0,0,1
96,miR-509-3p alteration of YAP1/ECM axis WP3967,0.2534024320832485,3.700140944326991,5.079466214399331,['GPC6'],0.6590539392586497,0,0,1
97,PPAR-alpha pathway WP2878,0.2534024320832485,3.700140944326991,5.079466214399331,['DBI'],0.6590539392586497,0,0,1
98,Osteoblast differentiation WP4787,0.2694335587650856,1.69921875,2.2284123147919166,"['FZD9', 'MAPK1', 'WNT9A']",0.6590539392586497,0,0,3
99,Serotonin Receptor 2 and ELK-SRF/GATA4 signaling WP732,0.271375151459444,3.391472868217054,4.4233389770622225,['MAPK1'],0.6590539392586497,0,0,1
100,Signal Transduction of S1P Receptor WP26,0.271375151459444,3.391472868217054,4.4233389770622225,['MAPK1'],0.6590539392586497,0,0,1
101,STING pathway in Kawasaki-like disease and COVID-19 WP4961,0.271375151459444,3.391472868217054,4.4233389770622225,['IKBKE'],0.6590539392586497,0,0,1
102,T-Cell Receptor and Co-stimulatory Signaling WP2583,0.271375151459444,3.391472868217054,4.4233389770622225,['ZAP70'],0.6590539392586497,0,0,1
103,Type II diabetes mellitus WP1584,0.271375151459444,3.391472868217054,4.4233389770622225,['MAPK1'],0.6590539392586497,0,0,1
104,Development and heterogeneity of the ILC family WP3893,0.271375151459444,3.391472868217054,4.4233389770622225,['IL18'],0.6590539392586497,0,0,1
105,Intraflagellar transport proteins binding to dynein WP4532,0.271375151459444,3.391472868217054,4.4233389770622225,['DYNLRB2'],0.6590539392586497,0,0,1
106,Nuclear Receptors Meta-Pathway WP2882,0.2862815022862054,1.3690021418950251,1.7123200589245198,"['GPR153', 'SERPINA1', 'ALOX5AP', 'TNFAIP3', 'DBI', 'SLC5A3']",0.6690286551859582,0,0,6
107,TGF-B Signaling in Thyroid Cells for Epithelial-Mesenchymal Transition WP3859,0.2889168464629168,3.1302921884317234,3.8866219951583427,['MAPK1'],0.6690286551859582,0,0,1
108,Blood Clotting Cascade WP272,0.2889168464629168,3.1302921884317234,3.8866219951583427,['F11'],0.6690286551859582,0,0,1
109,Physiological and pathological hypertrophy of the heart WP1528,0.2889168464629168,3.1302921884317234,3.8866219951583427,['MAPK1'],0.6690286551859582,0,0,1
110,Melanoma WP4685,0.3037334009685768,1.8514326140785284,2.2061762357524106,"['MAPK1', 'E2F3']",0.6690286551859582,0,0,2
111,Statin inhibition of cholesterol production WP430,0.30603781478400727,2.906423034330011,3.441340332128792,['APOC1'],0.6690286551859582,0,0,1
112,EPO Receptor Signaling WP581,0.30603781478400727,2.906423034330011,3.441340332128792,['MAPK1'],0.6690286551859582,0,0,1
113,Fatty Acid Biosynthesis WP357,0.30603781478400727,2.906423034330011,3.441340332128792,['ACAA2'],0.6690286551859582,0,0,1
114,IL-7 signaling pathway WP205,0.30603781478400727,2.906423034330011,3.441340332128792,['MAPK1'],0.6690286551859582,0,0,1
115,Ras signaling WP4223,0.31571006673049956,1.4307533539731683,1.6495598907314748,"['ZAP70', 'SHC3', 'MAPK1', 'RASAL3']",0.6690286551859582,0,0,4
116,Cannabinoid receptor signaling WP3869,0.32274810906654156,2.7124031007751936,3.067410848998662,['MAPK1'],0.6690286551859582,0,0,1
117,Ebstein-Barr virus LMP1 signaling WP262,0.32274810906654156,2.7124031007751936,3.067410848998662,['MAPK1'],0.6690286551859582,0,0,1
118,FGFR3 signaling in chondrocyte proliferation and terminal differentiation WP4767,0.32274810906654156,2.7124031007751936,3.067410848998662,['MAPK1'],0.6690286551859582,0,0,1
119,Follicle Stimulating Hormone (FSH) signaling pathway WP2035,0.32274810906654156,2.7124031007751936,3.067410848998662,['MAPK1'],0.6690286551859582,0,0,1
120,Purinergic signaling WP4900,0.32274810906654156,2.7124031007751936,3.067410848998662,['P2RX6'],0.6690286551859582,0,0,1
121,MicroRNAs in cardiomyocyte hypertrophy WP1544,0.33040427255849786,1.7327593343819854,1.9189240618809251,"['MAPK1', 'IKBKE']",0.6690286551859582,0,0,2
122,Non-small cell lung cancer WP4255,0.33040427255849786,1.7327593343819854,1.9189240618809251,"['MAPK1', 'E2F3']",0.6690286551859582,0,0,2
123,Angiogenesis WP1539,0.3390575427269803,2.5426356589147288,2.750077716676173,['MAPK1'],0.6690286551859582,0,0,1
124,Base Excision Repair WP4752,0.3390575427269803,2.5426356589147288,2.750077716676173,['TDG'],0.6690286551859582,0,0,1
125,TLR4 Signaling and Tolerance WP3851,0.3390575427269803,2.5426356589147288,2.750077716676173,['IKBKE'],0.6690286551859582,0,0,1
126,Fatty acid beta-oxidation WP143,0.3390575427269803,2.5426356589147288,2.750077716676173,['CPT1B'],0.6690286551859582,0,0,1
127,Hypothesized Pathways in Pathogenesis of Cardiovascular Disease WP3668,0.3390575427269803,2.5426356589147288,2.750077716676173,['MAPK1'],0.6690286551859582,0,0,1
128,RAS and bradykinin pathways in COVID-19 WP4969,0.3390575427269803,2.5426356589147288,2.750077716676173,['MAPK1'],0.6690286551859582,0,0,1
129,7-oxo-C and 7beta-HC pathways WP5064,0.35497569542919344,2.392840857273142,2.4782795262744886,['HSD11B2'],0.6690286551859582,0,0,1
130,Type II interferon signaling (IFNG) WP619,0.35497569542919344,2.392840857273142,2.4782795262744886,['HLA-B'],0.6690286551859582,0,0,1
131,Estrogen signaling pathway WP712,0.35497569542919344,2.392840857273142,2.4782795262744886,['MAPK1'],0.6690286551859582,0,0,1
132,IL1 and megakaryocytes in obesity WP2865,0.35497569542919344,2.392840857273142,2.4782795262744886,['IL18'],0.6690286551859582,0,0,1
133,Nanoparticle-mediated activation of receptor signaling WP2643,0.35497569542919344,2.392840857273142,2.4782795262744886,['MAPK1'],0.6690286551859582,0,0,1
134,"Relationship between inflammation, COX-2 and EGFR WP4483",0.35497569542919344,2.392840857273142,2.4782795262744886,['MAPK1'],0.6690286551859582,0,0,1
135,Disruption of postsynaptic signaling by CNV WP4875,0.3705119189948341,2.25968992248062,2.2435775757426777,['MAPK1'],0.6690286551859582,0,0,1
136,Eicosanoid metabolism via lipooxygenases (LOX) WP4721,0.3705119189948341,2.25968992248062,2.2435775757426777,['ALOX5'],0.6690286551859582,0,0,1
137,Fluoropyrimidine Activity WP1601,0.3705119189948341,2.25968992248062,2.2435775757426777,['TDG'],0.6690286551859582,0,0,1
138,Prolactin Signaling Pathway WP2037,0.37416816505844624,1.5653995809637833,1.538865969513842,"['ZAP70', 'MAPK1']",0.6690286551859582,0,0,2
139,Brain-derived neurotrophic factor (BDNF) signaling pathway WP2380,0.37491157210227166,1.3881392045454546,1.3618549116215817,"['SHC3', 'NCF2', 'MAPK1']",0.6690286551859582,0,0,3
140,Chemokine signaling pathway WP3929,0.37491157210227166,1.3881392045454546,1.3618549116215817,"['SHC3', 'MAPK1', 'CRKL']",0.6690286551859582,0,0,3
141,Focal Adhesion WP306,0.38144095233872943,1.292997198879552,1.2461896889687227,"['SHC3', 'MAPK1', 'MYL12A', 'CRKL']",0.6690286551859582,0,0,4
142,Type I collagen synthesis in the context of Osteogenesis imperfecta WP4786,0.3856753424013171,2.1405548755609956,2.0394336617903592,['TNFRSF11B'],0.6690286551859582,0,0,1
143,GABA receptor Signaling WP4159,0.3856753424013171,2.1405548755609956,2.0394336617903592,['GABRA4'],0.6690286551859582,0,0,1
144,Inflammatory Response Pathway WP453,0.3856753424013171,2.1405548755609956,2.0394336617903592,['ZAP70'],0.6690286551859582,0,0,1
145,Monoamine Transport WP727,0.3856753424013171,2.1405548755609956,2.0394336617903592,['TNFRSF11B'],0.6690286551859582,0,0,1
146,Resistin as a regulator of inflammation WP4481,0.3856753424013171,2.1405548755609956,2.0394336617903592,['MAPK1'],0.6690286551859582,0,0,1
147,SARS-CoV-2 mitochondrial interactions WP5038,0.3856753424013171,2.1405548755609956,2.0394336617903592,['IKBKE'],0.6690286551859582,0,0,1
148,Selenium Micronutrient Network WP15,0.39987279488118327,1.4795896710293597,1.3562049058235903,"['ALOX5', 'ALOX5AP']",0.6696481136279251,0,0,2
149,Wnt signaling in kidney disease WP4150,0.4004748773721285,2.033333333333333,1.860711959954748,['FZD9'],0.6696481136279251,0,0,1
150,Endothelin Pathways WP2197,0.4004748773721285,2.033333333333333,1.860711959954748,['MAPK1'],0.6696481136279251,0,0,1
151,mBDNF and proBDNF regulation of GABA neurotransmission WP4829,0.4004748773721285,2.033333333333333,1.860711959954748,['GABRA4'],0.6696481136279251,0,0,1
152,EGFR Tyrosine Kinase Inhibitor Resistance WP4806,0.40833253481971277,1.453029460811562,1.3014398377804088,"['SHC3', 'MAPK1']",0.6696481136279251,0,0,2
153,Insulin Signaling WP481,0.4139865920040326,1.2987865691489362,1.1454280487989832,"['SHC3', 'RHOJ', 'MAPK1']",0.6696481136279251,0,0,3
154,Host-pathogen interaction of human coronaviruses - interferon induction WP4880,0.41491922334593007,1.9363233665559247,1.7033283258957272,['IKBKE'],0.6696481136279251,0,0,1
155,Host-pathogen interaction of human coronaviruses - MAPK signaling WP4877,0.41491922334593007,1.9363233665559247,1.7033283258957272,['MAPK1'],0.6696481136279251,0,0,1
156,MAPK Cascade WP422,0.41491922334593007,1.9363233665559247,1.7033283258957272,['MAPK1'],0.6696481136279251,0,0,1
157,miRNA regulation of prostate cancer signaling pathways WP3981,0.41491922334593007,1.9363233665559247,1.7033283258957272,['MAPK1'],0.6696481136279251,0,0,1
158,Regucalcin in proximal tubule epithelial kidney cells WP4838,0.41491922334593007,1.9363233665559247,1.7033283258957272,['MAPK1'],0.6696481136279251,0,0,1
159,Type I interferon induction and signaling during SARS-CoV-2 infection WP4868,0.4290168725614852,1.8481324876673715,1.5639988078909317,['IKBKE'],0.6717833819905915,0,0,1
160,Heart Development WP1591,0.4290168725614852,1.8481324876673715,1.5639988078909317,['MAPK1'],0.6717833819905915,0,0,1
161,Overview of leukocyte-intrinsic Hippo pathway functions WP4542,0.4290168725614852,1.8481324876673715,1.5639988078909317,['RAB13'],0.6717833819905915,0,0,1
162,PDGF Pathway WP2526,0.4290168725614852,1.8481324876673715,1.5639988078909317,['MAPK1'],0.6717833819905915,0,0,1
163,CAMKK2  Pathway WP4874,0.44277611511514325,1.7676103808560837,1.4400563044489836,['MAPK1'],0.6717833819905915,0,0,1
164,G13 Signaling Pathway WP524,0.44277611511514325,1.7676103808560837,1.4400563044489836,['ARHGDIB'],0.6717833819905915,0,0,1
165,Histone Modifications WP2369,0.44277611511514325,1.7676103808560837,1.4400563044489836,['HIST1H3E'],0.6717833819905915,0,0,1
166,IL17 signaling pathway WP2112,0.44277611511514325,1.7676103808560837,1.4400563044489836,['MAPK1'],0.6717833819905915,0,0,1
167,Alpha 6 Beta 4 signaling pathway WP244,0.4562050434074691,1.693798449612403,1.3293148968633934,['MAPK1'],0.6717833819905915,0,0,1
168,Bladder cancer WP2828,0.4562050434074691,1.693798449612403,1.3293148968633934,['MAPK1'],0.6717833819905915,0,0,1
169,Notch Signaling WP268,0.4562050434074691,1.693798449612403,1.3293148968633934,['DTX3'],0.6717833819905915,0,0,1
170,EGF/EGFR signaling pathway WP437,0.4585500099527029,1.2079594678217822,0.9418289893204529,"['MAPK1', 'FOSB', 'CRKL']",0.6717833819905915,0,0,3
171,IL-6 signaling pathway WP364,0.46931155728093243,1.625891472868217,1.2299680874126702,['MAPK1'],0.6717833819905915,0,0,1
172,Neovascularisation processes WP4331,0.46931155728093243,1.625891472868217,1.2299680874126702,['MAPK1'],0.6717833819905915,0,0,1
173,Nephrotic syndrome WP4758,0.46931155728093243,1.625891472868217,1.2299680874126702,['E2F3'],0.6717833819905915,0,0,1
174,Pancreatic adenocarcinoma pathway WP4263,0.47375899726183285,1.2704280155642023,0.9490815464265353,"['MAPK1', 'E2F3']",0.6717833819905915,0,0,2
175,Apoptosis Modulation and Signaling WP1772,0.48163091242902906,1.2507632445375636,0.9137791091948355,"['TNFRSF11B', 'TNFRSF10D']",0.6717833819905915,0,0,2
176,ESC Pluripotency Pathways WP3931,0.48163091242902906,1.2507632445375636,0.9137791091948355,"['FZD9', 'MAPK1']",0.6717833819905915,0,0,2
177,Fragile X Syndrome  WP4549,0.48163091242902906,1.2507632445375636,0.9137791091948355,"['DLG4', 'MAPK1']",0.6717833819905915,0,0,2
178,TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway WP2036,0.48210336825207156,1.5632081097197377,1.140511526676746,['MAPK1'],0.6717833819905915,0,0,1
179,Fas ligand pathway and stress induction of heat shock proteins WP314,0.48210336825207156,1.5632081097197377,1.140511526676746,['ARHGDIB'],0.6717833819905915,0,0,1
180,Interleukin-11 Signaling Pathway WP2332,0.48210336825207156,1.5632081097197377,1.140511526676746,['MAPK1'],0.6717833819905915,0,0,1
181,Kisspeptin/kisspeptin receptor system in the ovary WP4871,0.48210336825207156,1.5632081097197377,1.140511526676746,['MAPK1'],0.6717833819905915,0,0,1
182,Monoamine GPCRs WP58,0.48210336825207156,1.5632081097197377,1.140511526676746,['DRD1'],0.6717833819905915,0,0,1
183,Regulation of Microtubule Cytoskeleton WP2038,0.48210336825207156,1.5632081097197377,1.140511526676746,['F2RL2'],0.6717833819905915,0,0,1
184,Wnt Signaling Pathway WP363,0.49458800407607606,1.5051679586563307,1.0596836658191715,['MAPK1'],0.6744381873764673,0,0,1
185,Envelope proteins and their potential roles in EDMD physiopathology WP4535,0.49458800407607606,1.5051679586563307,1.0596836658191715,['MAPK1'],0.6744381873764673,0,0,1
186,IL-5 signaling pathway WP127,0.49458800407607606,1.5051679586563307,1.0596836658191715,['MAPK1'],0.6744381873764673,0,0,1
187,Neural Crest Cell Migration during Development WP4564,0.49458800407607606,1.5051679586563307,1.0596836658191715,['F2RL2'],0.6744381873764673,0,0,1
188,Cholesterol metabolism (includes both Bloch and Kandutsch-Russell pathways) WP4718,0.5067728132376319,1.4512735326688815,0.9864197006871072,['ELOVL3'],0.6873780179552986,0,0,1
189,Vitamin A and carotenoid metabolism WP716,0.5186649688794933,1.401095963646084,0.9198154877953224,['MAPK1'],0.6961029845487936,0,0,1
190,Neural Crest Cell Migration in Cancer WP4565,0.5186649688794933,1.401095963646084,0.9198154877953224,['F2RL2'],0.6961029845487936,0,0,1
191,Aryl Hydrocarbon Receptor Netpath WP2586,0.5302714735033027,1.3542635658914728,0.8590990177590748,['MAPK1'],0.7006177499655036,0,0,1
192,Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway WP2203,0.5302714735033027,1.3542635658914728,0.8590990177590748,['MAPK1'],0.7006177499655036,0,0,1
193,Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms WP4534,0.5302714735033027,1.3542635658914728,0.8590990177590748,['ITGB2'],0.7006177499655036,0,0,1
194,Sterol regulatory element-binding proteins (SREBP) signaling WP1982,0.5415991623434937,1.3104526131532883,0.8036076818225666,['DBI'],0.7046315632530147,0,0,1
195,Translation inhibitors in chronically activated PDGFRA cells WP4566,0.5415991623434937,1.3104526131532883,0.8036076818225666,['MAPK1'],0.7046315632530147,0,0,1
196,Nucleotide-binding Oligomerization Domain (NOD) pathway WP1433,0.5415991623434937,1.3104526131532883,0.8036076818225666,['IL18'],0.7046315632530147,0,0,1
197,Genotoxicity pathway WP4286,0.552654707981765,1.2693798449612403,0.7527700098312252,['AMER1'],0.7117522754310609,0,0,1
198,Phosphodiesterases in neuronal function WP4222,0.552654707981765,1.2693798449612403,0.7527700098312252,['DRD1'],0.7117522754310609,0,0,1
199,Angiopoietin Like Protein 8 Regulatory Pathway WP3915,0.5632384572900144,1.0686053655539627,0.6134352534719594,"['SHC3', 'MAPK1']",0.7217377216530336,0,0,2
200,IL-4 signaling pathway WP395,0.5739752677321283,1.194482444140447,0.663139589588771,['MAPK1'],0.7232256109369402,0,0,1
201,Lung fibrosis WP3624,0.5739752677321283,1.194482444140447,0.663139589588771,['SERPINA1'],0.7232256109369402,0,0,1
202,Prostaglandin Synthesis and Regulation WP98,0.5739752677321283,1.194482444140447,0.663139589588771,['HSD11B2'],0.7232256109369402,0,0,1
203,TGF-beta Signaling Pathway WP366,0.583844493056662,1.0277298921341673,0.5530426371128304,"['MAPK1', 'FOSB']",0.7232256109369402,0,0,2
204,NRF2 pathway WP2884,0.583844493056662,1.0277298921341673,0.5530426371128304,"['SERPINA1', 'SLC5A3']",0.7232256109369402,0,0,2
205,Apoptosis-related network due to altered Notch3 in ovarian cancer WP2864,0.584252846482391,1.1602436323366556,0.6235397961541246,['MAPK1'],0.7232256109369402,0,0,1
206,Netrin-UNC5B signaling pathway WP4747,0.584252846482391,1.1602436323366556,0.6235397961541246,['MAPK1'],0.7232256109369402,0,0,1
207,Hippo-Merlin Signaling Dysregulation WP4541,0.5905525836734392,1.0147859922178988,0.5344843297025574,"['ITGB2', 'CDH13']",0.7250826396653693,0,0,2
208,Structural Pathway of Interleukin 1 (IL-1) WP2637,0.5942834183924007,1.127906976744186,0.586961592941248,['MAPK1'],0.7250826396653693,0,0,1
209,IL-1 signaling pathway WP195,0.5942834183924007,1.127906976744186,0.586961592941248,['MAPK1'],0.7250826396653693,0,0,1
210,Synaptic Vesicle Pathway WP2267,0.6040728975022165,1.097318248481039,0.5531146720756221,['SLC17A6'],0.73351708982412,0,0,1
211,Spinal Cord Injury WP2431,0.6101940432689353,0.9778256996859032,0.48302464620113883,"['TNFSF13', 'MAPK1']",0.734623941149241,0,0,2
212,The Overlap Between Signal Transduction Pathways that Contribute to a Range of LMNA Laminopathies WP4879,0.6136270567246601,1.0683394532843737,0.5217427325171543,['TNFRSF11B'],0.734623941149241,0,0,1
213,Oncostatin M Signaling Pathway WP2374,0.6136270567246601,1.0683394532843737,0.5217427325171543,['MAPK1'],0.734623941149241,0,0,1
214,AMP-activated protein kinase (AMPK) signaling WP1403,0.6229515312476637,1.0408467501490757,0.49261878013593785,['CPT1B'],0.742302058262403,0,0,1
215,Regulation of Actin Cytoskeleton WP51,0.6291122328151771,0.9434440322142793,0.4372349927930886,"['MAPK1', 'CD14']",0.7461563691528846,0,0,2
216,Thyroid stimulating hormone (TSH) signaling pathway WP2032,0.6409332982934033,0.9898846662885233,0.44033028355583714,['MAPK1'],0.7497155553432011,0,0,1
217,Complement and Coagulation Cascades WP558,0.6409332982934033,0.9898846662885233,0.44033028355583714,['SERPINA1'],0.7497155553432011,0,0,1
218,Prader-Willi and Angelman Syndrome WP3998,0.6409332982934033,0.9898846662885233,0.44033028355583714,['GNRH1'],0.7497155553432011,0,0,1
219,16p11.2 proximal deletion syndrome WP4949,0.6580606486173426,0.9436632413917433,0.39488360323659144,['SPN'],0.7621859163264502,0,0,1
220,"Non-genomic actions of 1,25 dihydroxyvitamin D3 WP4341",0.6580606486173426,0.9436632413917433,0.39488360323659144,['MAPK1'],0.7621859163264502,0,0,1
221,Endometrial cancer WP4155,0.6663166332012318,0.9221282593375617,0.37437512513679716,['MAPK1'],0.7621859163264502,0,0,1
222,RAC1/PAK1/p38/MMP2 Pathway WP3303,0.6663166332012318,0.9221282593375617,0.37437512513679716,['MAPK1'],0.7621859163264502,0,0,1
223,VEGFA-VEGFR2 Signaling Pathway WP3888,0.666539056238425,0.8894583677192373,0.3608146057667375,"['DOK1', 'PNP', 'NCF2', 'RHOJ', 'IDH2', 'MAPK1']",0.7621859163264502,0,0,6
224,Hepatitis B infection WP4666,0.6704704127881268,0.8718463662608259,0.34854299513170606,"['MAPK1', 'IKBKE']",0.7632587288436266,0,0,2
225,G1 to S cell cycle control WP45,0.6743740305234451,0.9015503875968992,0.35518414929866576,['E2F3'],0.7642905679265711,0,0,1
226,AGE/RAGE pathway WP2324,0.6822375992494111,0.8818672059319178,0.3372059974719834,['MAPK1'],0.7697813619849551,0,0,1
227,Alzheimer's disease WP2059,0.6899119845302563,0.8630216064654461,0.3203460673092953,['MAPK1'],0.7750112601551338,0,0,1
228,Chromosomal and microsatellite instability in colorectal cancer  WP4216,0.6974017204702669,0.8449612403100775,0.304518688964987,['MAPK1'],0.7765827018337034,0,0,1
229,ncRNAs involved in Wnt signaling in hepatocellular carcinoma WP4336,0.6974017204702669,0.8449612403100775,0.304518688964987,['FZD9'],0.7765827018337034,0,0,1
230,Leptin signaling pathway WP2034,0.7047112331426953,0.8276380319569688,0.2896461302752166,['MAPK1'],0.7813102802234231,0,0,1
231,LncRNA involvement in canonical Wnt signaling and colorectal cancer WP4258,0.7188067661405363,0.7950296397628819,0.262489141198303,['FZD9'],0.7934879885966959,0,0,1
232,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway WP3932,0.7274576160016566,0.8087843137254902,0.2573547977393415,"['CSF3R', 'CAB39L', 'ITGB2', 'MAPK1']",0.799576258967338,0,0,4
233,Retinoblastoma gene in cancer WP2446,0.738703094879527,0.7506459948320413,0.22734004910097644,['E2F3'],0.8069973091779491,0,0,1
234,MAPK Signaling Pathway WP382,0.7405387072456475,0.7779447115384616,0.2336769902462769,"['MAPK1', 'CD14', 'CRKL']",0.8069973091779491,0,0,3
235,Thermogenesis WP4321,0.7511817735817017,0.7236987818383167,0.20705573205400554,['CPT1B'],0.8147052714911389,0,0,1
236,Thyroid hormones production and their peripheral downstream signaling effects WP4746,0.7571966640917644,0.7109343125254998,0.19773377078006732,['MAPK1'],0.8147052714911389,0,0,1
237,Glioblastoma signaling pathways WP2261,0.7571966640917644,0.7109343125254998,0.19773377078006732,['MAPK1'],0.8147052714911389,0,0,1
238,DNA Repair Pathways Full Network WP4946,0.7630666984109178,0.698609997326918,0.1889110144658958,['TDG'],0.8175714625831262,0,0,1
239,Wnt signaling pathway and pluripotency WP399,0.7743860167576272,0.6751937984496124,0.17263679135543492,['FZD9'],0.8250953486323807,0,0,1
240,Circadian rhythm related genes WP3594,0.7765603281245935,0.703569615970225,0.17791935079667265,"['DRD1', 'CIART']",0.8250953486323807,0,0,2
241,Pathways in clear cell renal cell carcinoma WP4018,0.7798420041925807,0.6640615071800737,0.16512814981069593,['CDH13'],0.8251440293323986,0,0,1
242,7q11.23 copy number variation syndrome WP4932,0.7851665464547489,0.6532883220805201,0.1580039363787704,['FZD9'],0.8273449146527313,0,0,1
243,Senescence and Autophagy in Cancer WP615,0.7954338387479921,0.6327519379844961,0.14481642000824274,['MAPK1'],0.8347145221429547,0,0,1
244,Wnt signaling WP428,0.8003826738623867,0.6229576624925462,0.1387110693556565,['FZD9'],0.836465499323396,0,0,1
245,Pathways Regulating Hippo Signaling WP4540,0.8099253930019557,0.6042462108064329,0.12738304282346258,['CDH13'],0.842983572308158,0,0,1
246,Small cell lung cancer WP4658,0.814524935867022,0.5953032375740994,0.12212659996006353,['E2F3'],0.8443246286426448,0,0,1
247,DNA damage response (only ATM dependent) WP710,0.8276688465692414,0.5699858063107326,0.10780833993613924,['MAPK1'],0.8544759347172332,0,0,1
248,Cell cycle WP179,0.8398846290069361,0.5467211397443955,0.09539777788669945,['E2F3'],0.8601228128384285,0,0,1
249,Gastrin signaling pathway WP4659,0.8398846290069361,0.5467211397443955,0.09539777788669945,['MAPK1'],0.8601228128384285,0,0,1
250,Ectoderm Differentiation WP2858,0.8747055438086603,0.48117386489479513,0.06441376880984606,['TNFRSF11B'],0.8921996546848335,0,0,1
251,Integrated breast cancer pathway WP1984,0.8807057348430211,0.4698936361997476,0.05969139753051303,['MAPK1'],0.8947408859958978,0,0,1
252,Metapathway biotransformation Phase I and II WP702,0.8891735057156204,0.4539238742269837,0.053319211458232325,['CHST10'],0.8997589045931872,0,0,1
253,PI3K-Akt signaling pathway WP4172,0.9012201499364402,0.55859375,0.05809694050190612,"['CSF3R', 'MAPK1', 'PIK3AP1']",0.908344419896412,0,0,3
254,Ciliopathies WP4803,0.9415021927517887,0.35042130097741825,0.021122906095204327,['DNAAF3'],0.9452088942980555,0,0,1
255,Ciliary landscape WP4352,0.9482755883998936,0.33565891472868215,0.017826883196303683,['DYNLRB2'],0.9482755883998936,0,0,1
